Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|December 8, 2020
Regenecare HA Hydrogel Recalled
Author(s)Pharmaceutical Technology Editors
The product is being recalled because of Burkholderia cepecia contamination.
Advertisement
MPM Medical (Mesquite, TX)
Regenecare HA Hydrogel is a topical product is used for temporary relief of pain and itching associated with minor burns, sunburn, minor cuts, scrapes, insect bites or minor skin irritations. According to the company, use of product contaminated with B. cepacia could cause skin infections, which could spread into the blood stream in patients that are immunocompromised, leading to life-threatening sepsis.
The product is packaged in 3 oz. plastic tubes and was distributed nationwide to wholesalers and healthcare facilities in boxes of 12. The company has not received any reports of adverse events as of the date of the recall announcement. Adverse events may be reported to FDA through its MedWatch program.
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement